Coeliac Disease Study

Coeliac Disease is an autoimmune disorder that develops in genetically predisposed people. It involves an immune response to gluten containing foods such as wheat, barley and rye found in bread, cereals, pasta and baked goods. 

The only current treatment is to maintain a lifelong strict gluten free diet which can be extremely challenging and near impossible. The inevitable breaks in the diet result in uncomfortable symptoms such as diarrhoea, abdominal pain and bloating that disrupt everyday life. On top of this, availability of gluten free food varies between countries and regions and the cost is significantly higher than equivalent gluten containing food. 

As such, there is significant unmet medical need for safe and effective alternative treatments in addition to dietary avoidance of gluten.

This research study is investigating the effects of an investigational treatment on coeliac disease and specific immune and gut health markers during and after a gluten challenge.

Participants will receive an intravenous infusion of either the investigational treatment or a placebo (a substance with no active ingredients) once a week for eight doses over an 11-week period. Starting in Week 4, participants will begin a gluten challenge by consuming a small, measured amount of gluten daily for six weeks.

The study medication aims to reduce the body’s immune response to gluten which could represent a potential new treatment option for people living with coeliac disease.

Why join this clinical research study?

• Access a potential new treatment that may reduce gluten-related damage
• Receive close medical monitoring throughout the study
• Contribute to the development of potential treatments beyond gluten avoidance